AU2003275958A1
(en)
*
|
2003-08-25 |
2005-03-10 |
Pieris Proteolab Ag |
Muteins of tear lipocalin
|
EP1814988A2
(en)
|
2004-11-26 |
2007-08-08 |
Pieris AG |
Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
|
US7611847B2
(en)
|
2005-06-01 |
2009-11-03 |
Agency For Science, Technology And Research |
Method for identifying an intestinal phenotype
|
BRPI0621413A2
(pt)
|
2006-02-13 |
2011-12-06 |
Agency Science Tech & Res |
método de processamento de uma amostra biológica e/ou quìmica
|
JP4987885B2
(ja)
|
2006-03-09 |
2012-07-25 |
エージェンシー フォー サイエンス,テクノロジー アンド リサーチ |
小滴中で反応を行うための装置及びその使用方法
|
WO2007107563A2
(en)
*
|
2006-03-20 |
2007-09-27 |
Technische Universität München |
Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
|
CN101516907B
(zh)
*
|
2006-08-01 |
2015-08-26 |
皮里斯股份公司 |
泪液脂质运载蛋白的突变蛋白及其获得方法
|
WO2008015239A2
(en)
*
|
2006-08-01 |
2008-02-07 |
Pieris Ag |
Muteins of tear lipocalin and methods for obtaining the same
|
WO2010120249A1
(en)
|
2009-04-17 |
2010-10-21 |
Curiox Biosystems Pte Ltd |
Use of chemically patterned substrate for liquid handling, chemical and biological reactions
|
WO2008063135A1
(en)
|
2006-11-24 |
2008-05-29 |
Agency For Science, Technology And Research |
Apparatus for processing a sample in a liquid droplet and method of using the same
|
US9874501B2
(en)
|
2006-11-24 |
2018-01-23 |
Curiox Biosystems Pte Ltd. |
Use of chemically patterned substrate for liquid handling, chemical and biological reactions
|
JP2010523652A
(ja)
|
2007-04-13 |
2010-07-15 |
エージェンシー フォー サイエンス,テクノロジー アンド リサーチ |
腫瘍発生を制御する方法および腫瘍発生のリスクを診断する方法
|
US8969313B2
(en)
|
2007-11-02 |
2015-03-03 |
Agency For Science, Technology And Research |
Methods and compounds for preventing and treating a tumour
|
WO2013114217A1
(en)
|
2012-02-05 |
2013-08-08 |
Curiox Biosystems Pte Ltd. |
Array plates and methods for making and using same
|
US10725020B2
(en)
|
2007-11-14 |
2020-07-28 |
Curiox Biosystems Pte Ltd. |
High throughput miniaturized assay system and methods
|
CL2008003561A1
(es)
|
2007-11-30 |
2010-02-05 |
Glaxo Group Ltd |
Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias.
|
US20090274623A1
(en)
*
|
2008-01-30 |
2009-11-05 |
General Electric Company |
In vivo imaging agents for met receptor tyrosine kinase
|
US9212208B2
(en)
*
|
2008-01-30 |
2015-12-15 |
Pieris Ag |
Muteins with tear lipocalin having affinity to human c-Met receptor tyrosine kinase and methods for obtaining the same
|
US9051568B2
(en)
|
2008-04-25 |
2015-06-09 |
Rutgers, The State University Of New Jersey |
Anti-sense microrna expression vectors
|
WO2009136867A1
(en)
|
2008-05-06 |
2009-11-12 |
Agency For Science, Technology And Research |
Method of effecting de-differentiation of a cell
|
KR20110010758A
(ko)
|
2008-05-06 |
2011-02-07 |
글락소 그룹 리미티드 |
생물학적 활성제의 캡슐화
|
EP2313430B1
(en)
|
2008-06-24 |
2018-05-02 |
Technische Universität München |
Muteins of hngal and related proteins with affinity for a given target
|
JP2010074915A
(ja)
*
|
2008-09-17 |
2010-04-02 |
Jtekt Corp |
モータ制御装置及び電動パワーステアリング装置
|
US8716420B2
(en)
|
2008-10-13 |
2014-05-06 |
Agency For Science, Technology And Research |
Amphiphilic polymers and nanocrystals coated therewith
|
DK2189539T4
(en)
|
2008-11-21 |
2018-09-17 |
Chimera Biotec Gmbh |
Conjugate complexes for analyte detection
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
WO2010097394A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Multivalent and/or multispecific rankl-binding constructs
|
CA2753287A1
(en)
|
2009-02-24 |
2010-09-02 |
Glaxo Group Limited |
Antigen-binding constructs
|
US20110305693A1
(en)
|
2009-02-24 |
2011-12-15 |
Glaxo Group Limited |
Anitigen-binding constructs
|
JP2012532607A
(ja)
|
2009-07-07 |
2012-12-20 |
エージェンシー フォー サイエンス,テクノロジー アンド リサーチ |
一対の結合パートナーを同定する方法
|
WO2011012646A2
(en)
|
2009-07-28 |
2011-02-03 |
F. Hoffmann-La Roche Ag |
Non-invasive in vivo optical imaging method
|
JP2013501033A
(ja)
*
|
2009-08-05 |
2013-01-10 |
ピエリス アーゲー |
リポカリン突然変異タンパク質の制御放出製剤
|
DK2510357T3
(en)
|
2009-12-07 |
2016-07-18 |
Pieris Ag |
MUTEINS OF HUMAN LIPOCALIN 2 (LCN2, HNGAL) WITH AFFINITY FOR A SPECIFIC TARGET
|
CN102812348B
(zh)
|
2009-12-22 |
2016-02-03 |
新加坡科技研究局 |
基于sers的分析物检测
|
JP5850860B2
(ja)
|
2010-01-28 |
2016-02-03 |
グラクソ グループ リミテッドGlaxo Group Limited |
Cd127結合タンパク質
|
KR101341640B1
(ko)
*
|
2010-02-05 |
2013-12-16 |
한국전자통신연구원 |
단백질 미세 구조 분석 방법 및 단백질 미세 구조 분석용 어레이
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
CN107098958B
(zh)
|
2010-03-26 |
2021-11-05 |
达特茅斯大学理事会 |
Vista调节性t细胞介体蛋白、vista结合剂及其用途
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
KR20130036012A
(ko)
|
2010-05-07 |
2013-04-09 |
에프. 호프만-라 로슈 아게 |
생체외 세포의 검출을 위한 진단 방법
|
UY33421A
(es)
|
2010-06-03 |
2011-12-30 |
Glaxo Wellcome House |
Proteinas de union al antígeno humanizados
|
WO2011154420A2
(en)
|
2010-06-08 |
2011-12-15 |
Pieris Ag |
Tear lipocalin muteins binding il-4 r alpha
|
WO2012011877A2
(en)
|
2010-07-23 |
2012-01-26 |
Curiox Biosystems Pte Ltd |
Apparatus and method for multiple reactions in small volumes
|
KR20180088745A
(ko)
|
2010-08-16 |
2018-08-06 |
피어이스 파마슈티컬즈 게엠베하 |
헵시딘 결합 단백질
|
US8987415B2
(en)
|
2010-09-07 |
2015-03-24 |
Technische Universitaet Muenchen |
Recombinant bacterial lipocalin blc and uses thereof
|
WO2012033953A1
(en)
*
|
2010-09-08 |
2012-03-15 |
Halozyme, Inc. |
Methods for assessing and identifying or evolving conditionally active therapeutic proteins
|
AU2011331232B2
(en)
|
2010-11-15 |
2015-05-07 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3)
|
PT2643352T
(pt)
|
2010-11-23 |
2018-08-01 |
Glaxo Group Ltd |
Proteínas de ligação a antigénio para a oncostatina m (osm)
|
US20130236467A1
(en)
|
2010-11-24 |
2013-09-12 |
Jeremy Griggs |
Multispecific antigen binding proteins targeting hgf
|
US9221885B2
(en)
|
2010-12-02 |
2015-12-29 |
Pieris Ag |
Muteins of human lipocalin 2 with affinity for CTLA-4
|
WO2012136685A1
(en)
|
2011-04-04 |
2012-10-11 |
Pieris Ag |
Methods and compositions for anti-vegf and anti-c-met therapy
|
CN105601741A
(zh)
|
2011-04-15 |
2016-05-25 |
卡姆普根有限公司 |
多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
|
ES2953190T3
(es)
|
2011-05-27 |
2023-11-08 |
Glaxo Group Ltd |
Proteínas de unión a BCMA (CD269/TNFRSF17)
|
US9225772B2
(en)
|
2011-09-26 |
2015-12-29 |
Knoa Software, Inc. |
Method, system and program product for allocation and/or prioritization of electronic resources
|
AU2012327878A1
(en)
|
2011-10-28 |
2014-05-29 |
Patrys Limited |
PAT-LM1 epitopes and methods for using same
|
AU2012350654C1
(en)
|
2011-12-12 |
2018-05-10 |
Pieris Ag |
Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
|
CA2858962C
(en)
|
2011-12-13 |
2023-09-05 |
Pieris Ag |
Compositions of human tear lipocalin muteins and methods of use thereof
|
IL298330A
(en)
|
2011-12-30 |
2023-01-01 |
Halozyme Inc |
Ph20 polypeptide variants, formulations and uses thereof
|
EP2802341B1
(en)
|
2012-01-09 |
2019-03-06 |
Pieris Pharmaceuticals GmbH |
Methods for preventing, treating or diagnosing disorders
|
WO2013113851A1
(en)
|
2012-01-31 |
2013-08-08 |
Technische Universitaet Muenchen |
Muteins of a1m lipocalin and method of production therefor
|
PT2814843T
(pt)
|
2012-02-13 |
2020-06-18 |
Agency Science Tech & Res |
Anticorpos monoclonais humanos neutralizantes de il-b
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
US9522940B2
(en)
*
|
2012-05-23 |
2016-12-20 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
|
WO2013189521A1
(en)
|
2012-06-19 |
2013-12-27 |
Waclawczyk Simon |
Method of generating cells of hepatocyte phenotype
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
CA2884704C
(en)
|
2012-09-07 |
2023-04-04 |
Randolph J. Noelle |
Vista modulators for diagnosis and treatment of cancer
|
WO2014072306A1
(en)
|
2012-11-08 |
2014-05-15 |
F. Hoffmann-La Roche Ag |
Her3 antigen binding proteins binding to the beta-hairpin of her3
|
WO2014076321A1
(en)
|
2012-11-19 |
2014-05-22 |
Pieris Ag |
Novel specific-binding polypeptides and uses thereof
|
WO2014140210A1
(en)
|
2013-03-14 |
2014-09-18 |
Pieris Ag |
Novel binding proteins for pcsk9
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
US9557318B2
(en)
|
2013-07-09 |
2017-01-31 |
Curiox Biosystems Pte Ltd. |
Array plates for washing samples
|
US9388222B2
(en)
|
2013-10-06 |
2016-07-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified Pseudomonas exotoxin A
|
EP3074038B1
(en)
|
2013-11-28 |
2019-01-02 |
CSL Limited |
Method of treating diabetic nephropathy
|
KR20160096194A
(ko)
|
2013-12-18 |
2016-08-12 |
씨에스엘 리미티드 |
상처 치료 방법
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
MX369173B
(es)
|
2013-12-24 |
2019-10-30 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista.
|
AU2015205530B8
(en)
|
2014-01-13 |
2019-09-19 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
LU92409B1
(en)
|
2014-03-21 |
2015-09-22 |
Philipps Universit T Marburg |
Means and methods for itaconic acid production
|
CA2949405C
(en)
*
|
2014-05-22 |
2023-08-01 |
Pieris Pharmaceuticals Gmbh |
Novel specific-binding polypeptides and uses thereof
|
CN107073109B
(zh)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Vista激动剂和拮抗剂抑制或增强体液免疫的用途
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
HUE049982T2
(hu)
|
2014-11-14 |
2020-11-30 |
Hoffmann La Roche |
TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
|
WO2016090347A1
(en)
|
2014-12-05 |
2016-06-09 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
US11382963B2
(en)
|
2015-01-12 |
2022-07-12 |
Pieris Pharmaceuticals Gmbh |
Engineered T cells and uses therefor
|
CN107207574A
(zh)
|
2015-01-28 |
2017-09-26 |
皮里斯制药有限公司 |
血管生成特异性的新型蛋白
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
WO2016177762A1
(en)
*
|
2015-05-04 |
2016-11-10 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
CN107636014B
(zh)
|
2015-05-04 |
2021-12-07 |
皮里斯制药有限公司 |
抗癌融合多肽
|
HUE061108T2
(hu)
|
2015-05-18 |
2023-05-28 |
Pieris Pharmaceuticals Gmbh |
Rákellenes fúziós polipeptid
|
CA2982034A1
(en)
|
2015-05-18 |
2016-11-24 |
Pieris Pharmaceuticals Gmbh |
Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
|
US10545139B2
(en)
|
2015-06-16 |
2020-01-28 |
Curiox Biosystems Pte Ltd. |
Methods and devices for performing biological assays using magnetic components
|
BR112017027870A2
(pt)
|
2015-06-24 |
2018-08-28 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista
|
EP3115066A1
(en)
|
2015-07-07 |
2017-01-11 |
Technische Universität München |
Novel psma-specific binding proteins
|
CA2988831A1
(en)
|
2015-07-15 |
2017-01-19 |
Pieris Pharmaceuticals Gmbh |
Novel proteins specific for lag-3
|
BR112018000366A2
(pt)
|
2015-08-07 |
2018-09-11 |
Pieris Pharmaceuticals Gmbh |
polipeptídeo de fusão, muteína de lipocalina, molécula de ácido nucleico, célula hospedeira, métodos de produção de um polipeptídeo de fusão, para inibir simultaneamente os pontos de controle imunes, para aumentar a atividade celular de linfócitos antitumorais e para interferir com a ligação do lag-3 humano e uso do polipeptídeo de fusão
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
WO2017055404A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specific for pd1 and tim3
|
EP3356403A2
(en)
|
2015-10-02 |
2018-08-08 |
H. Hoffnabb-La Roche Ag |
Bispecific antibodies specific for a costimulatory tnf receptor
|
MX2018004157A
(es)
|
2015-10-07 |
2019-04-01 |
F Hoffmann La Roche Ag |
Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador.
|
CA3004918A1
(en)
|
2015-11-30 |
2017-06-08 |
Pieris Australia Pty Ltd. |
Novel anti-angiogenic fusion polypeptides
|
TW201725212A
(zh)
|
2015-12-10 |
2017-07-16 |
第一三共股份有限公司 |
特異性於降鈣素基因相關胜肽的新穎蛋白
|
BR112018016461A2
(pt)
|
2016-02-12 |
2019-10-01 |
Janssen Pharmaceutica Nv |
anticorpos e fragmentos anti-vista, usos dos mesmos e métodos de identificação dos mesmos
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
MX2018012469A
(es)
|
2016-04-15 |
2019-07-04 |
Immunext Inc |
Anticuerpos vista antihumanos y uso de los mismos.
|
EP3455254B1
(en)
|
2016-05-11 |
2021-07-07 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
WO2018050902A2
(en)
|
2016-09-15 |
2018-03-22 |
Quadrucept Bio Limited |
Multimers, tetramers & octamers
|
CN110023339A
(zh)
|
2016-09-23 |
2019-07-16 |
Csl有限公司 |
凝血因子结合蛋白及其应用
|
WO2018087108A1
(en)
|
2016-11-09 |
2018-05-17 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
EP3554542A1
(en)
|
2016-12-19 |
2019-10-23 |
H. Hoffnabb-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
PL3559034T3
(pl)
|
2016-12-20 |
2021-04-19 |
F. Hoffmann-La Roche Ag |
Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
|
TW201829469A
(zh)
|
2017-01-03 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
包含抗4-1bb純系20h4.9之雙特異性抗原結合分子
|
EP3571219A1
(en)
|
2017-01-18 |
2019-11-27 |
Pieris Pharmaceuticals GmbH |
Lipocalin muteins with binding affinity for lag-3
|
WO2018134279A1
(en)
|
2017-01-18 |
2018-07-26 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptides specific for lag-3 and pd-1
|
EP3601346A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
CN110573528B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
MA49039A
(fr)
|
2017-04-04 |
2020-02-12 |
Hoffmann La Roche |
Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap
|
SG11201909154SA
(en)
|
2017-04-05 |
2019-10-30 |
Hoffmann La Roche |
Bispecific antibodies specifically binding to pd1 and lag3
|
EP3607580B1
(en)
|
2017-04-05 |
2023-05-31 |
Curiox Biosystems Pte Ltd. |
Methods, devices, and apparatus for washing samples on array plates
|
JP2020537668A
(ja)
|
2017-10-18 |
2020-12-24 |
シーエスエル リミティド |
ヒト血清アルブミン変異体およびその使用
|
US20210324108A1
(en)
|
2017-11-01 |
2021-10-21 |
Hoffmann-La Roche Inc. |
Bispecific 2+1 contorsbodies
|
EP3703746A1
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Novel tnf family ligand trimer-containing antigen binding molecules
|
AU2018359506A1
(en)
|
2017-11-01 |
2020-04-23 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted OX40 agonists
|
DK3717011T3
(da)
|
2017-11-29 |
2023-01-09 |
Csl Ltd |
Fremgangsmåde til behandling eller forebyggelse af iskæmi-reperfusionsskade
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
AU2019236372B2
(en)
|
2018-03-13 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
|
CN111655731A
(zh)
|
2018-03-13 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
PE20210652A1
(es)
|
2018-04-13 |
2021-03-26 |
Hoffmann La Roche |
Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl
|
WO2019243564A1
(en)
|
2018-06-21 |
2019-12-26 |
Technische Universitaet Muenchen |
Hepatitis b and/or hepatitis d-permissive cells and animals
|
CN112424228A
(zh)
|
2018-07-04 |
2021-02-26 |
豪夫迈·罗氏有限公司 |
新型双特异性激动性4-1bb抗原结合分子
|
HRP20230590T2
(hr)
|
2018-07-31 |
2024-02-16 |
Pieris Pharmaceuticals Gmbh |
Novi fuzijski protein specifičan za cd137 i pd-l1
|
JP7221379B2
(ja)
|
2018-10-01 |
2023-02-13 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗fapクローン212を含む二重特異性抗原結合分子
|
CN112654641A
(zh)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
具有与cd40的三价结合的双特异性抗原结合分子
|
WO2020127618A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted agonistic cd28 antigen binding molecules
|
TW202030204A
(zh)
|
2018-12-21 |
2020-08-16 |
瑞士商赫孚孟拉羅股份公司 |
靶向腫瘤之超促效cd28抗原結合分子
|
CA3124441A1
(en)
|
2019-02-26 |
2020-09-03 |
Pieris Pharmaceuticals Gmbh |
Novel fusion proteins specific for cd137 and gpc3
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
WO2020200960A1
(en)
|
2019-03-29 |
2020-10-08 |
Astrazeneca Ab |
Lipocalin mutein for treatment of asthma
|
AU2020253034A1
(en)
|
2019-03-29 |
2021-08-19 |
Pieris Pharmaceuticals Gmbh |
Inhaled administration of lipocalin muteins
|
WO2020208049A1
(en)
|
2019-04-12 |
2020-10-15 |
F. Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising lipocalin muteins
|
TW202115124A
(zh)
|
2019-06-26 |
2021-04-16 |
瑞士商赫孚孟拉羅股份公司 |
結合至cea之新穎抗原結合分子
|
WO2020260326A1
(en)
|
2019-06-27 |
2020-12-30 |
F. Hoffmann-La Roche Ag |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
WO2021089588A1
(en)
|
2019-11-04 |
2021-05-14 |
Pieris Pharmaceuticals Gmbh |
Her2/4-1bb bispecific fusion proteins for the treatment of cancer
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
CN116249709A
(zh)
|
2020-06-05 |
2023-06-09 |
皮里斯制药有限公司 |
靶向4-1bb的多聚体免疫调节剂
|
US20220017637A1
(en)
|
2020-06-23 |
2022-01-20 |
Hoffmann-La Roche Inc. |
Agonistic cd28 antigen binding molecules targeting her2
|
WO2021260064A1
(en)
|
2020-06-25 |
2021-12-30 |
F. Hoffmann-La Roche Ag |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
JP2023549316A
(ja)
|
2020-11-16 |
2023-11-24 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Fapを標的としたcd40アゴニストとの併用療法
|
WO2022129629A1
(en)
|
2020-12-18 |
2022-06-23 |
Astrazeneca Ab |
Lipocalin mutein dry powder formulation for treatment of asthma
|
EP4274658A1
(en)
|
2021-01-06 |
2023-11-15 |
F. Hoffmann-La Roche AG |
Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
|
MX2023009100A
(es)
|
2021-02-03 |
2023-09-25 |
Mozart Therapeutics Inc |
Agentes aglutinantes y métodos para usar los mismos.
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
CN117355319A
(zh)
|
2021-03-23 |
2024-01-05 |
皮里斯制药有限责任公司 |
用于癌症治疗的her2/4-1bb双特异性融合蛋白
|
MX2023011780A
(es)
|
2021-04-08 |
2023-10-11 |
Pieris Pharmaceuticals Gmbh |
Nuevas muteinas de lipocalina especificas para factor de crecimiento de tejido conectivo (ctgf).
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
WO2023279092A2
(en)
|
2021-07-02 |
2023-01-05 |
Genentech, Inc. |
Methods and compositions for treating cancer
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
WO2023089079A1
(en)
|
2021-11-19 |
2023-05-25 |
Pieris Pharmaceuticals Gmbh |
Novel fusion protein specific for ox40 and pd-l1
|
TW202340248A
(zh)
|
2021-12-20 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
促效性ltbr抗體及包含其之雙特異性抗體
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
WO2024056862A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof
|
WO2024064713A1
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Novel fusion protein specific for cd137 and cd228
|
GB202216503D0
(en)
|
2022-11-05 |
2022-12-21 |
Quadrucept Bio Ltd |
Non-human vertebrates & cells
|